Cite
HARVARD Citation
Suleman, K. et al. (n.d.). Retrospective review of Her2 positive metastatic breast cancer patients who received Pertuzumab and Herceptin as a first line therapy at KFSH&RC (single institute experience) from 2013 to 2016. Breast. pp. S64-. [Online].